

# Annulated butanolides by ring closing metathesis of diallyltetronic acid derivatives

Rainer Schobert\* and Juan Manuel Urbina-González

*Organisch-chemisches Laboratorium der Universität, 95440 Bayreuth, Germany*

Received 3 March 2005; revised 21 March 2005; accepted 22 March 2005

Available online 6 April 2005

**Abstract**—3,3-Diallyldihydrofuran-2,4-diones **5** with two identical allyl residues were obtained by Tsuji–Trost-type Pd-catalysed allylation of either 4-*O*-allyltetronates or 3-allyltetronic acids. Allylation of sodium 3-allyltetronate with a second allyl acetate gave mixed derivatives **5** as did the Claisen rearrangement of 4-*O*-allyl 3-allyltetronates **6** under microwave conditions. Compounds **5** and **6** were converted to butanolides with 3,3-spirocyclopentenyl or 3,4-cycloalkanyl annulation by ring closing metathesis with Grubbs catalysts.


© 2005 Elsevier Ltd. All rights reserved.

Numerous fungal and plant metabolites with spiro-annulated  $\gamma$ -butyrolactone structures have been reported over the last few decades. As part of our ongoing efforts towards the structural cores of the bakkanes,<sup>1</sup> for example bakkenolide **A** **1**,<sup>2</sup> and of compounds like longianone **2**<sup>3</sup> we explored the feasibility of double allylation-ring closing metathesis sequences. 3,3-Diallyldihydrofuran-2,4-diones with identical allyl residues have been obtained by allylation of tetronic acids with either allyl halides/base followed by thermal Claisen rearrangement of the intermediate 3,4-diallyl tetronates,<sup>4,5</sup> or with allyl acetates under Pd catalysis resulting in moderate yields or product mixtures.<sup>6</sup> Congeners with two different allyl residues were not accessible likewise. A single ring closing metathesis, namely of symmetrical 3,3-diallyldihydrofuran-2,4-dione has been reported.<sup>7</sup> In this paper we investigate the generality of such and similar approaches to 3-spiro and 4-spiro-

annulated or 3,4-fused butanolides as occurring in natural products.


The most serious obstacle to using Pd-mediated allylation protocols<sup>8</sup> is the mobility of allyl residues attached to either the 3- or the 4-position of tetronic acids in the presence of Pd<sup>0</sup>, which fact reflects the reversibility of the C–C bond formation step under the customary conditions. Both 3-allyltetronic acid **3**<sup>9</sup> and 4-*O*-allyl tetronates **4** when treated with Pd(Ph<sub>3</sub>P)<sub>4</sub> in toluene at ca. 80 °C ‘disproportionated’ to give 30–40% of the corresponding 3,3-diallyldihydrofuran-2,4-diones **5** besides a similar quantity of easy to separate de-allylated tetronic acids. The latter can also be converted to **5** by reaction with an excess of external allyl acetate in the presence of Pd<sup>0</sup> and of a base such as DBU to increase their solubility. As depicted in Scheme 1, symmetrical 3,3-diallyldihydrofuran-2,4-diones **5a–c** were obtained in good yields from 4-*O*-allyltetronates **4** and allyl acetate.<sup>10</sup> 3-Allyl-3-cinnamyldihydrofuran-2,4-dione **5d**, however, was formed merely as a mixture with **5a** and 3,3-di-cinnamyldihydrofuran-2,4-dione, when allyltetronate **4a** was treated with cinnamyl acetate (Scheme 1).

Yet ‘mixed’ 3,3-diallyl derivatives were accessible in two other ways. The first one exploits the fact that the above mentioned Pd-mediated scrambling of allyl residues requires elevated temperatures. By deprotonating 3-allyltetronic acids with sodium alkoxides well soluble sodium tetronate salts with a more strongly nucleophilic tetronate anion are obtained.<sup>11</sup> These in turn are readily allylated by a second external allyl acetate at 0 °C



**Keywords:** Tetronic acid; Metathesis; Spiro compounds; Microwave.


\*Corresponding author. Tel.: +49 0921 552680; fax: +49 0921 552671; e-mail: [rainer.schobert@uni-bayreuth.de](mailto:rainer.schobert@uni-bayreuth.de)





**Scheme 1.** 3,3-Diallyldihydrofuran-2,4-diones **5** from 4-*O*-allyltetronates and allyl acetates under Tsuji conditions; (a) + **5a** (26%) + 3,3-dicinnamylidihydrofuran-2,4-dione (36%).

without scrambling of the allyl residues at a noticeable degree (Scheme 2, top).<sup>12</sup> An alternative high-yielding route to mixed 3,3-diallyldihydrofuran-2,4-diones **5** consists of the esterification of 3-allyltetronic acids such as **3** with a different allylic alcohol<sup>13</sup> followed by a thermal Claisen rearrangement of the intermediate 4-*O*-allyl 3-allyltetronate **6** (Scheme 2, bottom).<sup>14</sup> When carried out under microwave irradiation the Claisen step proceeded quantitatively and without allyl scrambling. The esterification of **3** with methallylic alcohol to give **6a** was only possible under modified Mitsunobu conditions<sup>15</sup> while both the Steglich–Hassner as well as our own isourea<sup>16</sup> method failed completely.


Ring closing metathesis reactions were then carried out with bis-allyl tetronates of types **5** and **6** to build up the structural target motifs of butanolides with 3,3-spirocyclopentenyl, with 4,4-spiro-oxacycloalkanyl and with 3,4-cycloalkanyl annulation. Metathesis reaction of various 3,3-diallyldihydrofuran-2,4-diones **5** with Grubbs catalysts gave 3,3-spirocyclopentenylidihydrofuran-2,4-diones **7** in good to excellent yields (Scheme 3, top). While first generation catalyst (Pcy<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub>Ru=CHPh was efficacious in the RCM of derivatives with two C<sub>3</sub>H<sub>5</sub> residues,<sup>17</sup> a second generation catalyst and harsh conditions were required for the ring closure of **5e**, most likely due to sterical hinderance.<sup>18,19</sup> Residual Ru compounds responsible for a greyish to black hue of the crude prod-



**Scheme 2.** Mixed 3,3-diallyldihydrofuran-2,4-diones **5d,e**; (a) + **5a** (8%) + 3,3-dicinnamylidihydrofuran-2,4-dione (5%).




<sup>a)</sup> Grubbs catalysts:



**Scheme 3.** 3,3-Spirocyclopentenylidihydrofuran-2,4-diones **7** and 3,4-dispirobutanolide **8**.

ucts were removed by treatment with 4 mol % of lead tetraacetate according to Paquette et al.<sup>20</sup> We then treated **7a** with ethyl sorbate in order to complete the bakane framework via a Diels–Alder reaction with the cyclopentene. No reaction was observed under classical thermal (PhMe, sealed tube, 180 °C) nor under Lewis acid catalysed [2 mol % Yb(OTf)<sub>3</sub> or EtAlCl<sub>2</sub>, 180 °C, PhMe] conditions. However, when compound **7a** was heated with Danishefsky's diene in a sealed tube in toluene the corresponding hetero-Diels Alder 3,4-dispiro adduct **8** was obtained instead in 50% yield after chromatography and recrystallisation (Scheme 3, middle).<sup>21</sup>

RCM of 4-*O*-allyl 3-allyltetronates **6** led to the corresponding furo[3,4-*b*]dihydrooxepines **9**. Again, the allyl-methallyl derivative **6a** required a second generation Grubbs catalyst and forcing conditions causing a concomitant shift of the double bond into a conjugated position furnishing **9b** (Scheme 4).<sup>17,18</sup> Alkene



**Scheme 4.** Furo[3,4-*b*]dihydrooxepines **9**.

isomerisation as a side or a follow-up reaction to metathesis processes initiated with Grubbs catalysts has been frequently reported, especially for allylic alcohols and allyl ethers.<sup>22</sup>

In conclusion two efficient syntheses of 3,3-diallyldihydrofurandiones-2,4 **5** with different allyl residues were developed, one by Pd-catalysed Tsuji allylation of the sodium salts of 3-allyltetronic acids, the other by Claisen rearrangement of 4-*O*-allyl 3-allyltetronates. Ring-closing metathesis of **5** with Grubbs catalysts furnished 3-spirocyclopentenylidihydrofurandiones-2,4 **7** while RCM of the 4-*O*-allyl 3-allyltetronate precursors gave furo[3,4-*b*]dihydrooxepinones **9**. In line with the known literature on RCM, the proper choice of the catalyst very much depends on the degree of substitution of the olefins.

### Acknowledgements

Financial support from the Deutsche Forschungsgemeinschaft (Grant Scho 402/7-1) is gratefully acknowledged.

### References and notes

- (a) Fischer, N. H.; Oliver, E. J.; Fischer, H. D. In *Progress in the Chemistry of Organic Natural Products*; Herz, W., Grisebach, H., Kirby, G. W., Eds.; Springer: New York, 1979; Vol. 38, Chapter 2; (b) Silva, L. F. *Synthesis* **2001**, 671–689.
- (a) Abe, N.; Onoda, R.; Shirahata, K.; Kato, T.; Woods, M. C.; Kitahara, Y. *Tetrahedron Lett.* **1968**, 9(3), 369–373; (b) Brocksom, T. J.; Coelho, F.; Depres, J.; Greene, A. E.; Freire de Lima, M. E.; Hamelin, O.; Hartmann, B.; Kanazawa, A.; Wang, Y. *J. Am. Chem. Soc.* **2002**, 124, 15313–15325.
- Edwards, R. L.; Maitland, D. J.; Oliver, C. L.; Pacey, M. S.; Shields, L.; Whalley, A. J. S. *J. Chem. Soc., Perkin Trans. 1* **1999**, 715–719.
- Momose, T.; Toyooka, N.; Nishio, M.; Shinoda, H.; Fujii, H.; Yanagino, H. *Heterocycles* **1999**, 51(6), 1321–1343.
- Kotha, S.; Mandal, K.; Deb, A. C.; Banerjee, S. *Tetrahedron Lett.* **2004**, 45, 9603–9605.
- (a) Prat, M.; Moreno-Mañas, M.; Ribas, J. *Tetrahedron* **1988**, 44(23), 7205–7212; (b) Moreno-Mañas, M.; Prat, M.; Ribas, J.; Virgili, A. *Tetrahedron Lett.* **1988**, 29(5), 581–584.
- Kotha, S.; Deb, A. C.; Kumar, R. V. *Bioorg. Med. Chem. Lett.* **2005**, 15(4), 1039–1043.
- Tsuji, J. In *Handbook of Organopalladium Chemistry for Organic Synthesis*; Negishi, E., Ed.; John Wiley & Sons, 2002, p 1669.
- Schobert, R.; Gordon, G. J.; Mullen, G.; Stehle, R. *Tetrahedron Lett.* **2004**, 45(6), 1121–1124.
- Compound **5a**<sup>7</sup> from **4a**—typical procedure: **4a**<sup>12</sup> (500 mg, 3.6 mmol), Pd(Ph<sub>3</sub>P)<sub>4</sub> (80 mg, 2 mol %), allyl acetate (390 mg, 3.9 mmol) and toluene (10 mL) were stirred in the dark at 85 °C for 2 h. Filtration over Celite<sup>®</sup>, removal of the solvent and column chromatography (CC) (silica gel 60; hexane/Et<sub>2</sub>O, 2:3, v/v; *R*<sub>f</sub> 0.78) left a colourless liquid (418 mg, 65%); *v*<sub>max</sub> (ATR)/cm<sup>−1</sup> 1802, 1752, 1214; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 2.44 (4H, d, <sup>3</sup>*J* 7.3 Hz), 4.35 (2H, s), 5.08 (2H, d, <sup>3</sup>*J* 9.7 Hz), 5.09 (2H, d, <sup>3</sup>*J* 17.3 Hz), 5.57 (2H, ddt, <sup>3</sup>*J* 7.3, 9.7, 17.3 Hz); <sup>13</sup>C NMR (75.5 MHz, CDCl<sub>3</sub>): δ 38.9, 53.9, 73.2, 121.2, 129.9, 175.6, 209.9; *m/z* (EI) 180 (M<sup>+</sup>, 2%), 139 (64%), 79 (95%), 41 (100%). Compound **5b**: *R*<sub>f</sub> 0.73 (hexane/Et<sub>2</sub>O, 3:2), red oil; *v*<sub>max</sub> (ATR)/cm<sup>−1</sup> 1797, 1751, 1211; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 0.98 (3H, t, <sup>3</sup>*J* 7.5 Hz), 1.51–1.69 (1H, m), 1.72–1.89 (1H, m), 2.41 (4H, d, <sup>3</sup>*J* 7.7 Hz), 4.29 (1H, dd, <sup>3</sup>*J* 4.5, 8.6 Hz), 5.01–5.12 (4H, m), 5.46–5.65 (2H, m); <sup>13</sup>C NMR (75.5 MHz, CDCl<sub>3</sub>): δ 9.6, 23.8, 37.9, 40.3, 54.5, 85.7, 120.8, 121.2, 129.9, 130.8, 175.3, 211.7; *m/z* (EI) 208 (M<sup>+</sup>, 5%), 166 (33%), 79 (100%), 41 (79%). Compound **5c**: *R*<sub>f</sub> 0.83 (hexane/Et<sub>2</sub>O, 3:2), yellow oil; *v*<sub>max</sub> (ATR)/cm<sup>−1</sup> 1798, 1755, 1214; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 0.83 (3H, t, <sup>3</sup>*J* 7.2), 1.10–1.40 (4H, m), 1.40–1.60 (1H, m), 1.65–1.87 (1H, m), 2.41 (4H, dm, <sup>3</sup>*J* 7.5 Hz), 4.34 (1H, dd, <sup>3</sup>*J* 4.3, 9.1 Hz), 5.05 (2H, m), 5.11 (2H, m), 5.45–5.70 (2H, m); <sup>13</sup>C NMR (75.5 MHz, CDCl<sub>3</sub>): δ 13.6, 22.0, 27.3, 30.1, 38.1, 40.3, 54.5, 84.7, 120.8, 121.2, 129.9, 130.8, 175.4, 211.9; *m/z* (EI) 236 (M<sup>+</sup>, 5%), 194 (14%), 79 (100%), 41 (29%).
- Sodeoka, M.; Sampe, R.; Kojima, S.; Baba, Y.; Morisaki, N.; Hashimoto, Y. *Chem. Pharm. Bull.* **2001**, 49(2), 206–212.
- Compound **5d** from **3**: **3** (200 mg, 1.43 mmol), NaOMe (79.5 mg, 1.43 mmol) and dry MeOH (10 mL) were stirred at rt for 2 h. The solvent was removed to give a hygroscopic sodium salt, which was re-dissolved in THF/MeOH and stirred with Pd(Ph<sub>3</sub>P)<sub>4</sub> (32 mg, 2 mol %) and cinnamyl acetate (276 mg, 1.57 mmol) at 0 °C in the dark for 2 h. Filtration over Celite<sup>®</sup>, concentration and CC (silica gel 60; hexane/Et<sub>2</sub>O, 2:3, v/v; *R*<sub>f</sub> 0.72) left a colourless oil (292 mg, 80%); *v*<sub>max</sub> (ATR)/cm<sup>−1</sup> 1801, 1753, 1218; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 2.48 (2H, d, <sup>3</sup>*J* 7.3 Hz), 2.59 (2H, d, <sup>3</sup>*J* 7.4 Hz), 4.30 (2H, s), 5.10 (1H, dd, <sup>3</sup>*J* 10.2, <sup>2</sup>*J* 1.5 Hz), 5.10 (1H, dd, <sup>3</sup>*J* 17.0, <sup>2</sup>*J* 1.5 Hz), 5.56 (1H, ddt, <sup>3</sup>*J* 17.0, 10.2, 7.3 Hz), 5.93 (1H, dt, <sup>3</sup>*J* 15.8, 7.4 Hz), 6.40 (1H, d, <sup>3</sup>*J* 15.8 Hz), 7.12–7.24 (5H, m); <sup>13</sup>C NMR (75.5 MHz, CDCl<sub>3</sub>): δ 38.3, 39.1, 54.3, 73.3, 120.8, 121.3, 126.4, 127.9, 128.3, 129.9, 136.0, 136.1, 175.8, 210.1; *m/z* (EI) 256 (M<sup>+</sup>, 4%), 215 (6%), 117 (100%), 104 (35%).
- Compound **6a** from **3**: DIAD (940 mg, 4.65 mmol) was added dropwise to Ph<sub>3</sub>P (1.22 g, 4.65 mmol) in THF (10 mL) at −78 °C whereupon a white solid formed. **3** (500 mg, 3.57 mmol) in THF (5 mL) was slowly added at −78 °C. After addition of methallylic alcohol (390 mg, 5.41 mmol) to the clear solution it was warmed to rt while stirring and treated with aqueous NaHCO<sub>3</sub> solution (pH 10) and Et<sub>2</sub>O (3 × 10 mL). Drying and concentrating of the organic layers and CC (silica gel 60; hexane/Et<sub>2</sub>O, 2:3, v/v; *R*<sub>f</sub> 0.57) of the residue afforded a colourless oil (519 mg, 75%); *v*<sub>max</sub> (ATR)/cm<sup>−1</sup> 1746, 1667, 1045; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 1.72 (3H, s), 2.94 (2H, d, <sup>3</sup>*J* 6.2 Hz), 4.49 (2H, s), 4.64 (2H, s), 4.95 (2H, m), 4.96 (2H, mc), 5.81 (1H, ddt, <sup>3</sup>*J* 6.2, 10.0, 17.0 Hz); <sup>13</sup>C NMR (75.5 MHz, CDCl<sub>3</sub>): δ 18.7, 26.2, 65.5, 73.6, 101.2, 113.8, 115.5, 134.2, 139.2, 172.4, 174.3; *m/z* (EI) 194 (M<sup>+</sup>, 10%), 161 (27%), 139 (60%), 55 (100%).
- Compound **5e** from **6a**: **6a** (500 mg, 2.57 mmol) in toluene (8 mL) was irradiated in a microwave oven (CEM Discovery<sup>®</sup>) at 190 °C for 20 min. Removal of the solvent and CC (silica gel 60; hexane/Et<sub>2</sub>O, 2:3, v/v; *R*<sub>f</sub> 0.76) left a colourless oil (500 mg, 100%); *v*<sub>max</sub> (ATR)/cm<sup>−1</sup> 1804, 1754, 1044; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 1.65 (3H, dd, <sup>4</sup>*J* 0.9, 1.4 Hz), 2.47 (2H, ddd, <sup>3</sup>*J* 7.3, <sup>4</sup>*J* 1.4, 1.2 Hz), 2.50 (2H, s), 4.38 (2H, s), 4.68 (1H, m), 4.83 (1H, m), 5.12 (1H, m), 5.13 (1H, m), 5.60 (1H, ddt, <sup>3</sup>*J* 17.3, 9.7, 7.3 Hz); <sup>13</sup>C NMR (75.5 MHz, CDCl<sub>3</sub>): δ 23.8, 40.3, 42.6, 54.2, 73.6, 116.1, 121.4, 129.8, 139.4, 176.2, 210.2; *m/z* (EI) 194 (M<sup>+</sup>,

- 2%), 176 (50%), 139 (88%), 55 (100%). Satisfactory microanalyses (C, 0.2; H, 0.1) were obtained for **5a–e**.
15. Tahir, H.; Hindsgaul, O. *J. Org. Chem.* **2000**, *65*, 911–913.
16. Schobert, R.; Siegfried, S. *Synlett* **2000**, 686–687.
17. Compound **7a** from **5a**—typical procedure: **5a** (330 mg, 1.8 mmol) dissolved in dry CH<sub>2</sub>Cl<sub>2</sub> (15 mL) was treated with (Pcy<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub>RuCHPh (30 mg, 2 mol %) and the mixture was stirred for 24 h at rt. Pb(OAc)<sub>4</sub> (32 mg, 4 mol %) was added and stirring was continued for a further 20 h. Filtration over a Celite® plug (3 cm), concentration of the filtrates and CC (silica gel 60; Et<sub>2</sub>O; *R<sub>f</sub>* 0.64) left a white powder (250 mg, 90%), mp 72 °C; *v*<sub>max</sub> (ATR)/cm<sup>−1</sup> 1781, 1745, 1246, 1047; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 2.70–2.92 (4H, m), 4.65 (2H, s), 5.65 (2H, s); <sup>13</sup>C NMR (75.5 MHz, CDCl<sub>3</sub>): δ 42.4, 50.8, 72.1, 127.4, 177.6, 209.3; *m/z* (EI) 152 (M<sup>+</sup>, 80%), 110 (41%), 94 (33%), 66 (100%). Compound **7b**: *R<sub>f</sub>* 0.63 (hexane/Et<sub>2</sub>O, 2:3), yellow oil; *v*<sub>max</sub> (ATR)/cm<sup>−1</sup> 1796, 1747, 1242, 1046; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 0.99 (3H, t, <sup>3</sup>*J* 7.4 Hz), 1.70–1.88 (1H, m), 1.88–2.05 (1H, m), 2.68 (1H, d, <sup>2</sup>*J* 16.5 Hz), 2.74 (1H, d, <sup>2</sup>*J* 16.2 Hz), 2.86 (1H, d, <sup>2</sup>*J* 16.5 Hz), 2.86 (1H, d, <sup>2</sup>*J* 16.2 Hz), 4.70 (1H, dd, <sup>3</sup>*J* 4.8, 7.0 Hz), 5.63 (2H, s); <sup>13</sup>C NMR (75.5 MHz, CDCl<sub>3</sub>): δ 8.8, 24.7, 42.1, 43.2, 50.9, 84.7, 126.9, 127.6, 177.4, 211.7; *m/z* (EI) 180 (M<sup>+</sup>, 73%), 110 (13%), 94 (95%), 66 (100%). Compound **7c**: *R<sub>f</sub>* 0.59 (hexane/Et<sub>2</sub>O, 2:3), yellow oil; *v*<sub>max</sub> (ATR)/cm<sup>−1</sup> 1798, 1749, 1250, 1052; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 0.84 (3H, t, <sup>3</sup>*J* 6.9 Hz), 1.22–1.45 (4H, m), 1.60–1.76 (1H, m), 1.77–1.95 (1H, m), 2.65 (1H, d, <sup>2</sup>*J* 15.7 Hz), 2.70 (1H, d, <sup>2</sup>*J* 15.5 Hz), 2.82 (1H, d, <sup>2</sup>*J* 15.7 Hz), 2.83 (1H, d, <sup>2</sup>*J* 15.5 Hz), 4.71 (1H, dd, <sup>3</sup>*J* 4.5, 7.9 Hz), 5.60 (2H, s); <sup>13</sup>C NMR (75.5 MHz, CDCl<sub>3</sub>): δ 13.5, 21.9, 26.6, 30.9, 42.2, 43.1, 50.8, 83.7, 126.9, 127.5, 177.3, 211.7; *m/z* (EI) 208 (M<sup>+</sup>, 21%), 110 (5%), 94 (100%), 66 (84%). Compound **9a**: *R<sub>f</sub>* 0.32 (hexane/Et<sub>2</sub>O, 2:3), white powder, mp 86 °C; *v*<sub>max</sub> (ATR)/cm<sup>−1</sup> 1734, 1662, 1019, 921; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 3.08 (2H, ddd, <sup>3</sup>*J* 5.6, <sup>4</sup>*J* 1.5, <sup>5</sup>*J* 1.6 Hz), 4.46 (2H, t, <sup>5</sup>*J* 1.6 Hz), 4.73 (2H, dd, <sup>3</sup>*J* 7.0, <sup>4</sup>*J* 0.4 Hz), 5.96 (1H, dtt, <sup>3</sup>*J* 7.0, 10.4, <sup>4</sup>*J* 1.5 Hz), 6.25 (1H, ddt, <sup>3</sup>*J* 5.6, 10.4, <sup>4</sup>*J* 0.4 Hz); <sup>13</sup>C NMR (75.5 MHz, CDCl<sub>3</sub>): δ 22.1, 66.7, 67.6, 99.6, 125.4, 137.2, 174.1, 174.2; *m/z* (EI) 152 (M<sup>+</sup>, 70%), 66 (100%), 54 (49%), 39 (59%).
18. Compound **7d** from **5e**—typical procedure: **5e** (250 mg, 1.8 mmol) dissolved in dry toluene (15 mL) was treated with benzylidene-[1,3-bis-(2,4,6-trimethylphenyl)-2-imidazolidinylidene]-dichloro(tricyclohexylphosphane)ruthenium C<sub>46</sub>H<sub>65</sub>Cl<sub>2</sub>N<sub>2</sub>PRu (44 mg, 4 mol %) and the mixture was stirred at 110 °C for 24 h. Pb(OAc)<sub>4</sub> (23 mg, 4 mol %) was added at rt and stirring was continued for a further 20 h. Workup as for **7a** gave a colourless oil of *R<sub>f</sub>* 0.46 (Et<sub>2</sub>O); *v*<sub>max</sub> (ATR)/cm<sup>−1</sup> 1807, 1791, 1750, 1042; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 1.72 (3H, m), 2.60 (1H, dm, <sup>2</sup>*J* 15.3 Hz), 2.73 (1H, dm, <sup>2</sup>*J* 15.3 Hz), 2.69 (1H, dm, <sup>2</sup>*J* 17 Hz), 2.81 (1H, d, <sup>2</sup>*J* 17 Hz), 4.63 (2H, d, <sup>5</sup>*J* 1.7 Hz), 5.22 (1H, m); <sup>13</sup>C NMR (75.5 MHz, CDCl<sub>3</sub>): δ 15.6, 42.6, 45.4, 51.5, 72.1, 120.7, 137.4, 177.7, 209.2; *m/z* (EI) 166 (M<sup>+</sup>, 64%), 124 (41%), 93 (36%), 79 (100%). Compound **9b**: *R<sub>f</sub>* 0.77 (Et<sub>2</sub>O), colourless oil; *v*<sub>max</sub> (ATR)/cm<sup>−1</sup> 1747, 1647, 1009; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 1.10 (3H, d, <sup>3</sup>*J* 7.4 Hz), 2.77 (1H, m), 4.14 (1H, dd, <sup>3</sup>*J* 5.9, 10.9 Hz), 4.26 (1H, dd, <sup>3</sup>*J* 1.1, 10.9 Hz), 4.58 (2H, s), 5.85 (1H, dd, <sup>3</sup>*J* 5.1, 10.6 Hz), 6.05 (1H, d, <sup>3</sup>*J* 10.6 Hz); <sup>13</sup>C NMR (75.5 MHz, CDCl<sub>3</sub>): δ 16.6, 37.8, 66.4, 76.8, 102.3, 117.6, 137.0, 173.0, 173.4; *m/z* (EI) 166 (M<sup>+</sup>, 100%), 151 (59%), 124 (42%), 79 (74%). Satisfactory microanalyses (C, 0.2; H, 0.2) were obtained for **7a–c** and **9a,b**.
19. A similar observation has been reported recently for the RCM of 2,3-bisalkenylcyclopentanones to give [5.7]bicycles: Michalak, K.; Michalak, M.; Wicha, J. *Tetrahedron Lett.* **2005**, *46*(7), 1149–1153.
20. Paquette, L. A.; Schloss, J. D.; Efremov, I.; Fabris, F.; Gallou, F.; Méndez-Andino, J.; Yang, J. *Org. Lett.* **2000**, *2*(9), 1259–1261.
21. Compound **8**: 1-Methoxy-3-trimethylsiloxy-1,3-butadiene (490 mg, 2.84 mmol) in toluene (10 mL) was treated with **7a** (220 mg, 1.45 mmol) at 0 °C and the resulting mixture was heated in a sealed tube for 3 days at 180 °C. 15 mL of a mixture of THF (35 mL) and 0.1 N aqueous HCl (15 mL) were added at rt and stirring continued for 1 min. The residual acid solution (35 mL) was added and the resulting solution poured into AcOEt (50 mL) and treated with H<sub>2</sub>O (25 mL). The organic layer was separated and the aqueous one was extracted with AcOEt (4 × 20 mL). The combined extracts were dried and concentrated and the residue was purified by CC (silica gel 60; Et<sub>2</sub>O; *R<sub>f</sub>* 0.53); white powder, mp 113 °C; *v*<sub>max</sub> (ATR)/cm<sup>−1</sup> 1767, 1675, 1039, 1005; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 2.46 (1H, dd, <sup>2</sup>*J* 17.2, <sup>4</sup>*J* 1.1 Hz), 2.53 (2H, m), 2.81 (1H, d, <sup>2</sup>*J* 17.2 Hz), 2.71–2.82 (1H, m), 2.84–2.95 (1H, m), 4.00 (1H, d, <sup>2</sup>*J* 10.6 Hz), 4.51 (1H, d, <sup>2</sup>*J* 10.6 Hz), 5.46 (1H, dd, <sup>3</sup>*J* 6.2, <sup>4</sup>*J* 1.1 Hz), 5.50–5.57 (1H, m), 5.70–5.77 (1H, m), 7.23 (1H, d, <sup>3</sup>*J* 6.2 Hz); <sup>13</sup>C NMR (75.5 MHz, CDCl<sub>3</sub>): δ 35.3, 37.4, 38.6, 54.9, 71.5, 88.9, 107.2, 125.9, 130.1, 160.9, 178.8, 188.5; *m/z* (EI) 220 (M<sup>+</sup>, 46%), 110 (97%), 91 (100%), 71 (91%). Found: C, 65.3; H, 5.6. C<sub>12</sub>H<sub>12</sub>O<sub>4</sub> requires C, 65.5; H, 5.5.
22. (a) Sutton, A. E.; Seigal, B. A.; Finnegan, D. F.; Snapper, M. L. *J. Am. Chem. Soc.* **2002**, *124*, 13390–13391; (b) Bourgeois, D.; Pancrazi, A.; Nolan, S. P.; Prunet, J. *J. Organomet. Chem.* **2002**, *643/644*, 247–252; (c) Sworen, J. C.; Pawlowa, J. H.; Case, W.; Lever, J.; Wagener, K. B. *J. Mol. Cat. A: Chem.* **2003**, *194*, 69–78; (d) Lehman, S. E.; Schwendeman, J. E.; O'Donnell, P. M.; Wagener, K. B. *Inorg. Chim. Acta* **2003**, *345*, 190–198.